[Correspondence] TRIBE2 results and toxicity – Authors’ reply

We thank Jianwei Zhang and colleagues for their considerations. Regarding patients with BRAF-mutated tumours, both in TRIBE1 and TRIBE22 no interaction effect between the study drugs and RAS or BRAF mutational status were observed. Therefore, the only methodologically appropriate conclusion is that the effect of the intensification of the upfront chemotherapy backbone is independent of RAS and BRAF mutational status.1,2

Lascia un commento